Article Details
Retrieved on: 2025-03-15 15:07:04
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
When patients with ROS1 fusion– positive disease have progression on these first-generation drugs, crizotinib and entrectinib [Rozlytrek], they ...
Article found on: www.targetedonc.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here